Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest VolitionRX Limited Stories

2013-03-26 08:28:57

SINGAPORE, March 26, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has hired Jason Terrell MD as Head of US Operations. Dr Terrell will initially be responsible for facilitating Volition's entry into the US market, acting as the company's FDA liaison and pursuing and negotiating FDA compliant US clinical trials. Dr Terrell has a strong grounding in both medicine and more specifically in...

2013-01-09 08:26:06

NAMUR, Belgium, Jan. 9, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it will commence a large internal clinical study for its Nucleosomics(®) diagnostic products this month. This trial is being undertaken in addition to its four ongoing external clinical trials. The trial will be carried out in Volition's laboratory on patient blood samples supplied by the Wales Cancer Bank...

2012-12-17 08:24:22

SINGAPORE, Dec. 17, 2012 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces the launch of NuQ(®), its range of research use only epigenetic immunoassays, to be available for sale at www.nucleosomics.com. The NuQ(®)( )products were launched at the Biochemical Society's Annual Symposium, "Epigenetic mechanisms in development and disease," held last week in Leeds, England. The NuQ(®) range of...

2012-11-05 08:30:54

SINGAPORE, Nov. 5, 2012 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, today announced preliminary findings from its ongoing internal clinical trials of the NuQ(®) diagnostic platform. VolitionRx has analysed blood samples from 105 patients and was able to detect 76% of the patients with colon cancer, 96% of those with breast cancer, and 100% of patients with lung cancer. Of the 105 patients tested, 74 had...

2012-08-21 02:26:36

SINGAPORE, Aug. 21, 2012 /PRNewswire/ -- VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium. This is the fourth large-scale external clinical trial for VolitionRX. The trial will begin in early September, and is scheduled for completion next year. The trial will be a prospective longitudinal study...

2012-07-16 02:23:48

SINGAPORE, July 16, 2012 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, issues the following letter to shareholders from CEO Cameron Reynolds: To our valued shareholders, It has been a very busy nine months since I last formally updated you. We have been moving forward on many fronts, and I am extremely happy with our team's progress in building our company. We are continuing to attract strong investment interest....

2012-07-09 02:24:29

SINGAPORE, July 9, 2012 /PRNewswire/ -- VolitionRX Limited (OTC:VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has entered into a collaboration agreement with Rheinische Friedrich-Wilhelms-Universitat Bonn ("Bonn University"), Germany. Under the agreement, Priv.-Doz. Dr. Stefan Holdenrieder of the Institute of Clinical Chemistry and Clinical Pharmacology at University Hospital Bonn will undertake multiple independent...

2012-05-14 02:27:36

SINGAPORE, May 14, 2012 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce the closure of a private placement of 582,510 shares at $1.75 per share (a total of US$$1,019,375.00 raised). The proceeds will in part be used to fund clinical trials of VolitionRX's first NuQ(TM)( )test kits. Shares in the offering were priced at $1.75 per ordinary share, which entitles the holder to one share of common...

2012-03-27 14:21:04

LONDON, March 27, 2012 /PRNewswire/ -- The ability to diagnose disease early has long been a goal in the medical arena. VolitionRX (VNRX.OB), a life sciences company, is pioneering scientific research into simple, cost-effective tools capable of diagnosing the early presence of disease via a blood test. (Photo: http://photos.prnewswire.com/prnh/20120327/NY77344 ) VolitionRX is developing its Nucleosomics(TM) technology to measure and identify the signatures of nucleosomes (a...

2012-02-17 04:00:00

SINGAPORE, Feb. 17, 2012 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, announces a collaboration agreement with Abcodia, a specialist company spun out from University College London (UCL), under which Volition will gain access to Abcodia's biobank of over 5,000,000 human serum samples to validate its suite of NuQ((TM)) tests. The samples, which were collected by scientists at UCL, will be used to validate Volition's...